Laboratory of Animal Physiology, Department of Zoology, School of Biology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, 9 Dúbravská cesta, 84104 Bratislava, Slovakia.
Int J Mol Sci. 2021 Jun 15;22(12):6399. doi: 10.3390/ijms22126399.
Accumulating evidence support the cardioprotective properties of the nuclear receptor peroxisome proliferator activated receptor β/δ (PPARβ/δ); however, the underlying mechanisms are not yet fully elucidated. The aim of the study was to further investigate the mechanisms underlying PPARβ/δ-mediated cardioprotection in the setting of myocardial ischemia/reperfusion (I/R). For this purpose, rats were treated with PPARβ/δ agonist GW0742 and/or antagonist GSK0660 in vivo and hearts were subjected to ex vivo global ischemia followed by reperfusion. PPARβ/δ activation improved left ventricular developed pressure recovery, reduced infarct size (IS) and incidence of reperfusion-induced ventricular arrhythmias while it also up-regulated superoxide dismutase 2, catalase and uncoupling protein 3 resulting in attenuation of oxidative stress as evidenced by the reduction in 4-hydroxy-2-nonenal protein adducts and protein carbonyl formation. PPARβ/δ activation also increased both mRNA expression and enzymatic activity of aldehyde dehydrogenase 2 (ALDH2); inhibition of ALDH2 abrogated the IS limiting effect of PPARβ/δ activation. Furthermore, upregulation of PGC-1α and isocitrate dehydrogenase 2 mRNA expression, increased citrate synthase activity as well as mitochondrial ATP content indicated improvement in mitochondrial content and energy production. These data provide new mechanistic insight into the cardioprotective properties of PPARβ/δ in I/R pointing to ALDH2 as a direct downstream target and suggesting that PPARβ/δ activation alleviates myocardial I/R injury through coordinated stimulation of the antioxidant defense of the heart and preservation of mitochondrial function.
越来越多的证据支持过氧化物酶体增殖物激活受体β/δ(PPARβ/δ)的心脏保护特性;然而,其潜在机制尚未完全阐明。本研究旨在进一步探讨心肌缺血/再灌注(I/R)中 PPARβ/δ介导的心脏保护作用的机制。为此,在体内用 PPARβ/δ 激动剂 GW0742 和/或拮抗剂 GSK0660 处理大鼠,并进行离体全心缺血后再灌注。PPARβ/δ 激活可改善左心室发展压恢复,减少梗死面积(IS)和再灌注引起的室性心律失常发生率,同时上调超氧化物歧化酶 2、过氧化氢酶和解偶联蛋白 3,从而减轻氧化应激,如 4-羟基-2-壬烯醛蛋白加合物和蛋白羰基形成减少所证实的那样。PPARβ/δ 激活还增加了醛脱氢酶 2(ALDH2)的 mRNA 表达和酶活性;ALDH2 抑制消除了 PPARβ/δ 激活对 IS 的限制作用。此外,PGC-1α 和异柠檬酸脱氢酶 2 mRNA 表达上调、柠檬酸合酶活性增加以及线粒体 ATP 含量增加表明线粒体含量和能量产生得到改善。这些数据为 PPARβ/δ 在 I/R 中的心脏保护特性提供了新的机制见解,指出 ALDH2 是直接下游靶点,并表明 PPARβ/δ 激活通过协调刺激心脏的抗氧化防御和维持线粒体功能来减轻心肌 I/R 损伤。